Tweetorial for UK docs using @CernerUK PowerChart (not sure if this format will be useful but here goes)
First a question: how would you rate yourself as a PowerChart user?
@HMRCcustomers if one receives a giro credit for a tax refund & it expires before it is deposited (not many banks have counters to accept these), how do you get one reissued (or a bank transfer instead)?
Online assistant suggests calling. After 1h, phone assistant says online 🤯
This study validates a previously reported bronchial signature of bronchiectasis in nasal epithelium. Changes in gene expression and cell-type composition associated with radiological bronchiectasis are similar across both bronchial and nasal epithelia. https://t.co/g7NwClYcoy
Inhaled anti-TSLP for persistent asthma -Phase 1 study
https://t.co/zUgROlymcm
AZD8630 well tolerated with low incidence of ADA
Suppression of FeNO indicating effects on airway epithelial cells and downstream IL13 signalling
@ProfJDChalmers What about patients not eligible eg non-eosinophilic - what’s in the pipeline for them?
And are there any plans to trial DPP1 inhibitors in COPD? (Question for both you and Mona!)
@ProfJDChalmers How do we ensure we select the right patients to see the benefit seen in trials - and ensure we can continue to prescribe these drugs? 2/
@ProfJDChalmers Very nice work!
Azurocidin-1 also elevated in some patients with asthma. I wonder if DPP1 inhibitors might be effective in airways disease, if we can appropriately select patients?
A study 10 years in the making, just published in @LancetRespirMed
How do DPP1 inhibitors really work in bronchiectasis?
We show a novel mechanism for treatment efficacy, by inhibiting Azurocidin-1, a ciliotoxin, DPP1i can enhance mucociliary clearance.
https://t.co/eVR7fhgW7w
ECCMID 2026
No induction of resistance over 6 months with monoclonal antibody therapy against pseudomonas in bronchiectasis
Encouraging beneficial changes to the microbiome too
Encouraging early results presented by @beccahull_
Inhaled immunoglobulin as a novel treatment for bronchiectasis: results from a phase 1 trial
Inhaled immunoglobulin G was associated with low rates of adverse events and reduced airway bacterial burden. Encouraging results! Online now at @ATSBlueEditor
https://t.co/4p6TayHxLq
People often ask how breakthroughs occur in cancer biology-often the story is more complex - the survival plot for myeloma outcomes is extraordinary - improvements come about in incremental steps - in my lifetime treatment of Myeloma has almost transformed into a curable disease
No cigar for Rilzabrutinib (BTK inhibitor) in mod-sev asthma (Ph 2)
Futility on primary EP of loss of asthma control upon withdawal of ICS/LABA
https://t.co/NgztQA48io
It makes no sense to me to close roads and dig them up just before a 4 day bank holiday with the disruption inevitably being extended by 4 more days?
@MayorofLondon can you make it prohibitively expensive to do this?
@CadentGasLtd@UKPowerNetworks@thameswater
Just counting blood vessels on #CT of #COPD pts predict lung function and its decline, exercise capacity & symptoms; better imaging biomarker of disease burden in #COPD than anything else we have https://t.co/lk0IVuLqJF
@DHSCgovuk@wesstreeting
Resident doctor strikes have highlighted all sorts of issues.
Not least the inefficient process to sign up to the bank to locum. Why do occupational health checks have to be in person? And why can’t in person ID checks be at the nearest hospital HR?
1/